Clinical Trial Update: To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies [Phase 2]

View source ↗

Summary

The document reports the results of a Phase 2 trial comparing subcutaneous canakinumab to placebo in people with impaired glucose tolerance or type 2 diabetes, …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Impaired Glucose Tolerance
• Type 2 Diabetes Mellitus

Drugs mentioned

• ILARIS (canakinumab)

Snippet

Sponsor: Novartis | Conditions: Type 2 Diabetes Mellitus, Impaired Glucose Tolerance | Phase 2 | Status: COMPLETED | Results posted: 2011-09-05